24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
MOZOLIEVA 24MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | MOZOLIEVA 24MG |
|---|---|
| Composition | Plerixafor Injection 24mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
Plerixafor Injection 24mg (Plerixafor Injection 24mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
MOZOLIEVA 24 mg contains Plerixafor, a hematopoietic stem cell mobilizer. It is a CXCR4 chemokine receptor antagonist that disrupts the interaction between CXCR4 and SDF-1α, causing rapid release of CD34+ stem cells from the bone marrow into peripheral blood for collection.
Plerixafor is used in combination with G-CSF for:
1. Mobilization of hematopoietic stem cells
– In patients with Non-Hodgkin’s Lymphoma (NHL)
– In Multiple Myeloma
2. Prior to autologous stem cell transplantation
Common side effects:
• Diarrhea
• Nausea
• Injection site reactions
• Fatigue
Other side effects:
• Dizziness
• Headache
Serious side effects (rare):
• Splenic enlargement or rupture
• Thrombocytopenia
Monitor WBC count and spleen size during treatment.
Dosage is based on body weight.
Standard dose:
• 0.24 mg/kg subcutaneous injection
• Given approximately 11 hours before apheresis
• Used after 4 days of G-CSF
24 mg vial is suitable for adult dosing.
NOTE: This medicine should be taken only under a doctor’s supervision.